公开(公告)号：US20250136685A1

公开(公告)日：2025-05-01

申请号：US18999104

申请日：2024-12-23

Applicant: Novartis AG

Inventor： Verena BRAND ,  Dominik FEUERBACH ,  Fabrizio GASPARINI ,  Nathalie GEORGE ,  Eveline SCHAADT ,  Derya SHIMSHEK ,  Honnappa SRINIVAS ,  Markus WALDHUBER ,  Rainer WILCKEN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61P25/28 ,  C12N7/00 ,  C12N15/70

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US20250101130A1

公开(公告)日：2025-03-27

申请号：US18655058

申请日：2024-05-03

Applicant: NOVARTIS AG

Inventor： Maximilian AIGNER ,  Alexander Wolfgang KOCH ,  Markus WALDHUBER

IPC: C07K16/40 ,  C07K16/36

Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20220162339A1

公开(公告)日：2022-05-26

申请号：US17450122

申请日：2021-10-06

Applicant: NOVARTIS AG

Inventor： Maximilian AIGNER ,  Alexander Wolfgang KOCH ,  Markus WALDHUBER

IPC: C07K16/40 ,  C07K16/36

Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20230167174A1

公开(公告)日：2023-06-01

申请号：US17934795

申请日：2022-09-23

Applicant: Novartis AG

Inventor： Verena BRAND ,  Dominik FEUERBACH ,  Fabrizio GASPARINI ,  Nathalie GEORGE ,  Eveline SCHAADT ,  Derya SHIMSHEK ,  Honnappa SRINIVAS ,  Markus WALDHUBER ,  Rainer WILCKEN

IPC: C07K16/28 ,  A61P25/28 ,  A61K39/395 ,  C12N7/00 ,  C12N15/70

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61P25/28 ,  C12N7/00 ,  C12N15/70 ,  A61K2039/505

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US20190330372A1

公开(公告)日：2019-10-31

申请号：US16472646

申请日：2017-12-21

Applicant: Novartis AG

Inventor： Maximillian AIGNER ,  Alexander Wolfgang KOCH ,  Markus WALDHUBER

IPC: C07K16/40 ,  C07K16/36

Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.